NCT05683834 2026-04-22
Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative Persons
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
Clinical Trials
8 trialsNCT06002802 2024-02-07
IMMUC
Technical University of Munich
Completed
NCT03546101 2023-10-31
Early Detection of Epstein-Barr Virus Related Disease.
University of Aarhus
Completed
NCT03650231 2018-08-28
DIAGEPS
Centre Hospitalier Universitaire, Amiens
Completed
NCT00359411 2017-07-02
Genetic Studies of X-linked Lymphoproliferative Disease
National Institutes of Health Clinical Center (CC)
Completed
NCT00575185 2017-03-22
Mono6
University of Minnesota
Phase 1/2 Completed
NCT00274404 2011-10-27
Controlled Trial of Valacyclovir in Infectious Mononucleosis
University of Minnesota
Phase 1/2 Completed
NCT00430534 2007-02-02
Evaluation of Safety, Immune-Response and Efficacy of GSK Biologicals' EBV (Epstein Barr Virus) Vaccine (268664).
Henogen
Phase 2 Completed